ALCL clinical trial results
| Protocol . | Chemotherapy backbone . | Study question . | Years . | No. of patients . | EFS . | OS . | Reference . |
|---|---|---|---|---|---|---|---|
| Pediatric | |||||||
| BFM 90 | BFM | Efficacy of B-cell protocol in ALCL | 1990-1995 | 89 | 76% (5 y) | — | 7 |
| LNH97 | BFM | Efficacy of B-cell protocol in ALCL | 1997-2000 | 32 | 68% (5 y) | 87% (5 y) | 17 |
| ALCL99 | BFM | Randomized MTX 1 g/m2 over 24 hours + IT vs 3 g/m2 over 3 hours and no IT | 1999-2005 | 352 | 74% (2 y) | 93% (2 y) | 12 |
| Randomized addition of vinblastine to induction therapy and maintenance vinblastine | 1999-2006 | 217 | 71% (2 y) | 94 (2 y) | 13 | ||
| ANHL12P1 | BFM | Addition of BV to ALCL99 chemotherapy backbone | 2013-2017 | 68 | 79% (2 y) | 97% (2 y) | 15 |
| Addition of crizotinib to ALCL99 chemotherapy backbone | 2013-2019 | 66 | 77% (2 y) | 95% (2 y) | 16 | ||
| SCCCG-ALCL-2017 | BFM | Risk stratify patients and add ALK inhibitor or vinblastine | 2015-2022 | 136 | 78% (3 y) | 92% (3 y) | 25 |
| HM89-91 | FAB/LMB | Efficacy of B-cell protocol in ALCL | 1988-1997 | 82 | 66% (3 y) | 83% (3 y) | 6 |
| NHL 9000 | FAB/LMB | Efficacy of B-cell protocol in ALCL | 1990-1998 | 72 | 59% (5 y) | 65% (5 y) | 8 |
| POG9315 | APO | Randomized APO maintenance vs APO maintenance alternating with IDM/HiDAC | 1994-2000 | 86 | 72% (4 y) | 88% (4 y) | 10 |
| ANHL0131 | APO | Randomized APO vs APO with vinblastine instead of vincristine | 2004-2008 | 125 | 76% (3 y) | 85% (3 y) | 14 |
| LNH92 | T cell | Efficacy of T-cell leukemia protocol | 1993-1997 | 34 | 65% (10 y) | 85% (10 y) | 9 |
| CCG-5941 | T cell | Efficacy of intensive T-cell protocol | 1996-2001 | 86 | 68% (5 y) | 80% (5 y) | 11 |
| Adult | |||||||
| ECHELON-2 | CHOP | Randomized CHOP vs BV-CHP | 2013-2016 | 154 | 48% (5 y) | 69% (5 y) | 26 |
| 162 | 61% (5 y) | 76% (5 y) |
| Protocol . | Chemotherapy backbone . | Study question . | Years . | No. of patients . | EFS . | OS . | Reference . |
|---|---|---|---|---|---|---|---|
| Pediatric | |||||||
| BFM 90 | BFM | Efficacy of B-cell protocol in ALCL | 1990-1995 | 89 | 76% (5 y) | — | 7 |
| LNH97 | BFM | Efficacy of B-cell protocol in ALCL | 1997-2000 | 32 | 68% (5 y) | 87% (5 y) | 17 |
| ALCL99 | BFM | Randomized MTX 1 g/m2 over 24 hours + IT vs 3 g/m2 over 3 hours and no IT | 1999-2005 | 352 | 74% (2 y) | 93% (2 y) | 12 |
| Randomized addition of vinblastine to induction therapy and maintenance vinblastine | 1999-2006 | 217 | 71% (2 y) | 94 (2 y) | 13 | ||
| ANHL12P1 | BFM | Addition of BV to ALCL99 chemotherapy backbone | 2013-2017 | 68 | 79% (2 y) | 97% (2 y) | 15 |
| Addition of crizotinib to ALCL99 chemotherapy backbone | 2013-2019 | 66 | 77% (2 y) | 95% (2 y) | 16 | ||
| SCCCG-ALCL-2017 | BFM | Risk stratify patients and add ALK inhibitor or vinblastine | 2015-2022 | 136 | 78% (3 y) | 92% (3 y) | 25 |
| HM89-91 | FAB/LMB | Efficacy of B-cell protocol in ALCL | 1988-1997 | 82 | 66% (3 y) | 83% (3 y) | 6 |
| NHL 9000 | FAB/LMB | Efficacy of B-cell protocol in ALCL | 1990-1998 | 72 | 59% (5 y) | 65% (5 y) | 8 |
| POG9315 | APO | Randomized APO maintenance vs APO maintenance alternating with IDM/HiDAC | 1994-2000 | 86 | 72% (4 y) | 88% (4 y) | 10 |
| ANHL0131 | APO | Randomized APO vs APO with vinblastine instead of vincristine | 2004-2008 | 125 | 76% (3 y) | 85% (3 y) | 14 |
| LNH92 | T cell | Efficacy of T-cell leukemia protocol | 1993-1997 | 34 | 65% (10 y) | 85% (10 y) | 9 |
| CCG-5941 | T cell | Efficacy of intensive T-cell protocol | 1996-2001 | 86 | 68% (5 y) | 80% (5 y) | 11 |
| Adult | |||||||
| ECHELON-2 | CHOP | Randomized CHOP vs BV-CHP | 2013-2016 | 154 | 48% (5 y) | 69% (5 y) | 26 |
| 162 | 61% (5 y) | 76% (5 y) |
FAB/LMB, French-American-British/Lymphomes Malins B; IDM/HiDAC, intermediate-dose methotrexate/high-dose cytarabine; IT, intrathecal therapy; MTX, methotrexate.